All In Biotech

Drug Trial Radar · NCT05785767

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

149

Actual

Start

Jun 30, 2023

Primary completion

Sep 28, 2027

Study completion Sep 28, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in your blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) * How administering the study drugs might improve your quality of life

Conditions

  • Advanced Non-Small Cell Lung Cancer

Interventions

  • fianlimabDrug

    Administered per the protocol

  • cemiplimabDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) as assessed by blinded independent central review (BICR), using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Time frame: Up to 136 weeks

Locations

106 sites in 11 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center

    Tucson, Arizona

  • Yuma Regional Medical Center

    Yuma, Arizona

  • Emad Ibrahim, MD, Inc.

    Redlands, California

  • Eastern CT Hematology and Oncology Associates

    Norwich, Connecticut

  • Clermont Oncology Center

    Clermont, Florida

  • Miami Veterans Administration HealthCare System

    Miami, Florida

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • Pinellas Hematology and Oncology

    St. Petersburg, Florida

  • Tallahassee Memorial Healthcare

    Tallahassee, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Illinois

    Chicago, Illinois

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana

  • Hattiesburg Clinic

    Hattiesburg, Mississippi

  • Mercy South

    St Louis, Missouri

  • St. Vincent Healthcare

    Billings, Montana

  • New Mexico Cancer Care Alliance

    Albuquerque, New Mexico

  • Clinical Research Alliance Inc

    Westbury, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Renovatio Clinical

    El Paso, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia Medical Center

    Charlottesville, Virginia

  • Bon Secours Cancer Institute Richmond

    Midlothian, Virginia

  • Macquarie University Health Science Center (MQ Health)

    Macquarie Park, New South Wales, Australia

  • Riverina Cancer Care Centre (RCCC)

    Wagga Wagga, New South Wales, Australia

  • Southern Medical Day Care Centre

    Wollongong, New South Wales, Australia

  • Ballarat Regional Integrated Cancer Centre (BRICC)

    Ballarat, Victoria, Australia

  • Bendigo Hospital

    Bendigo, Victoria, Australia

  • British Columbia Cancer Center-Kelowna

    Kelowna, British Columbia, Canada

  • Israeli Georgian Medical Research Clinic Helsicore

    Tbilisi, Georgia

  • Research Institute of Clinical Medicine

    Tbilisi, Georgia

  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

    Tbilisi, Georgia

  • NNLE New Vision University Hospital

    Tbilisi, Georgia

  • The Institute of Clinical Oncology

    Tbilisi, Georgia

  • TIM - Tbilisi Institute of Medicine

    Tbilisi, Georgia

  • JSC Evex Hospitals - Caraps Medline

    Tbilisi, Georgia

  • Cancer Center of Adjara

    Batumi, Adjara, Georgia

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Assuta Medical Centers

    Tel Aviv, Israel

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.